What is levodropropizine, including its indications, dosage for various age groups, contraindications, side effects, and alternative antitussive options?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Levodropropizine: A Peripheral Antitussive Agent

Levodropropizine is a peripherally-acting, non-opioid antitussive drug that suppresses cough by activating C-fiber sensory afferents to reflexively inhibit the cough reflex, demonstrating approximately 75% cough suppression in patients with chronic or acute bronchitis. 1

What is Levodropropizine?

Levodropropizine is a peripheral antitussive that works fundamentally differently from traditional central cough suppressants like codeine or dextromethorphan. Rather than acting on the central nervous system, it acts on the sensory nerve endings in the airways themselves 1. This peripheral mechanism means it lacks the sedation, abuse potential, and respiratory depression risks associated with opioid-based central antitussives 1.

The drug works by activating C-fiber sensory afferents, which then reflexively inhibit the cough reflex—a unique mechanism among antitussives 1.

Clinical Indications

Strongly Recommended For:

In patients with chronic or acute bronchitis, levodropropizine is recommended for short-term symptomatic relief of coughing (Grade A recommendation, good evidence, substantial benefit) 1.

The evidence shows:

  • Approximately 75% suppression of cough in patients with chronic or acute bronchitis 1
  • Efficacy comparable to dihydrocodeine for cough due to lung cancer 1
  • Meta-analysis of 1,178 patients demonstrated statistically significant superiority over central antitussives (codeine, cloperastine, dextromethorphan) in reducing cough intensity, frequency, and nocturnal awakenings (p = 0.0015) 2

Not Recommended For:

In patients with cough due to upper respiratory infections (URI), peripheral cough suppressants including levodropropizine have limited efficacy and are not recommended (Grade D recommendation, good evidence, no benefit) 1.

One study showed effects were restricted to nighttime cough only with limited magnitude of suppression in URI patients 1.

Dosage by Age Group

Adults:

  • 60 mg three times daily for 3-4 days of therapy 3
  • This dosing was effective in reducing cough frequency from 34.1 ± 5.6 to 20.4 ± 5.4 episodes (p < 0.05) 3

Pediatric Patients:

  • 2 mg/kg orally three times daily for 3 days 4
  • This dosing produced statistically significant decreases in coughing frequency and nocturnal awakenings (p < 0.001) 4
  • Demonstrated superior safety profile compared to dropropizine (racemic form), with half the incidence of daytime somnolence (5.3% vs 10.3%) 4

Safety Profile and Side Effects

Levodropropizine has an excellent safety profile with minimal central nervous system effects 5, 2:

  • Gastrointestinal symptoms: Mild when present 4
  • Somnolence: Only 5.3% incidence in children (significantly lower than other antitussives) 4
  • No respiratory depression: Critical advantage over opioid antitussives 1
  • No abuse potential: Unlike codeine or other central agents 5

Important Safety Data:

In patients with interstitial lung disease, levodropropizine showed no adverse effects on respiratory function—PaO2, PaCO2, and pH values remained unchanged before and after treatment 3. This is crucial because it demonstrates the drug does not suppress the respiratory drive, a major concern with central antitussives.

Contraindications

The evidence provided does not specify absolute contraindications. However, based on the mechanism and safety data:

  • Use caution in patients requiring productive cough for airway clearance
  • The drug is not approved for use in the United States 1

Alternative Antitussive Options

For Chronic Bronchitis:

  1. Central antitussives (codeine, dextromethorphan) - Grade B recommendation for short-term use 1
  2. Ipratropium bromide (inhaled anticholinergic) - Grade A recommendation 1

Key Distinction:

While central antitussives are effective, they carry risks of:

  • Sedation (except dextromethorphan)
  • Respiratory depression (opioids)
  • Abuse potential (codeine, hydrocodone)
  • These concerns are particularly relevant in pediatric populations 6

Clinical Pearls and Pitfalls

Common Pitfall: Using levodropropizine for URI-associated cough. The evidence clearly shows limited efficacy in this population 1. Reserve it for bronchitis-related cough.

Therapeutic Advantage: Recent pharmacokinetic analysis suggests that patients with higher eosinophil levels have increased plasma exposure to levodropropizine 7. This may represent a therapeutic advantage in inflammatory respiratory diseases where eosinophilia is present, as these patients may derive greater benefit from the drug.

Pediatric Consideration: Levodropropizine represents one of the few antitussives with documented efficacy and acceptable safety in children 6, 8. Traditional agents (codeine, dextromethorphan, antihistamines) have been deemed inadequate for pediatric acute cough on a risk/benefit basis 6.

Availability Limitation

Critical Note: Levodropropizine is not approved for use in the United States 1. It is available in other countries including India and various European nations 5. US practitioners must use alternative agents such as dextromethorphan or codeine (where appropriate).

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.